MedTrace Logo

Pharmacokinetic Study of Synera™ in Neonates and Infants

NCT00747669 · Status: SUSPENDED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2012-03-23

No results posted yet for this study

Summary

This study will measure the amount of lidocaine and tetracaine in the blood after a 30 minute application of Synera.

Conditions

Interventions

DRUG

lidocaine 70mg and tetracaine 70mg topical patch

One Synera Patch applied for 30 minutes.

Sponsors & Collaborators

  • ZARS Pharma Inc.

    lead INDUSTRY

Principal Investigators

  • ZARS Clinical Development · ZARS Pharma

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
4 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00747669 on ClinicalTrials.gov